Zacks Investment Management Biomarin Pharmaceutical Inc Transaction History
Zacks Investment Management
- $8.87 Billion
- Q2 2024
A detailed history of Zacks Investment Management transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Zacks Investment Management holds 21,573 shares of BMRN stock, worth $1.51 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
21,573
Previous 19,962
8.07%
Holding current value
$1.51 Million
Previous $1.74 Million
1.89%
% of portfolio
0.02%
Previous 0.02%
Shares
4 transactions
Others Institutions Holding BMRN
# of Institutions
630Shares Held
184MCall Options Held
1.63MPut Options Held
1.2M-
Black Rock Inc. New York, NY22.7MShares$1.59 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$1.33 Billion0.03% of portfolio
-
Primecap Management CO Pasadena, CA18.8MShares$1.31 Billion1.14% of portfolio
-
Dodge & Cox San Francisco, CA13.9MShares$974 Million0.72% of portfolio
-
Capital Research Global Investors Los Angeles, CA9.69MShares$678 Million0.18% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $13B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...